


Achaogen
Investor Relations Department
7000 Shoreline Court,
3rd Floor
South San Francisco, CA 94080
United States

[Visit IR website](#) 
[Sign-up for email alerts](#) 

NASDAQ: AKAO

Last Trade:	13.00
Trade Time:	2:24 PM ET Apr 24, 2018
Change:	-0.07  (0.536%)
Day Range	12.80 - 13.49
52-Week Range	9.83 - 27.49
Volume	632,179

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Achaogen is a late-stage biopharmaceutical company passionately committed to the discovery, development, and commercialization of innovative antibacterial treatments against multi-drug resistant (MDR), gram-negative infections. We are developing plazomicin, our lead product candidate, for the treatment of serious bacterial infections, including complicated urinary tract infections (cUTI), bloodstream infections and other infections due to MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae (CRE). In 2013, the Centers for Disease Control and Prevention identified CRE... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Apr 23, 2018*
[Achaogen Highlights Plazomicin Presentations at European Congress of Clinical Microbiology and Infectious Diseases \(ECCMID\)](#)
- Apr 10, 2018*
[Achaogen Announces Multiple Plazomicin Presentations at European Congress of Clinical Microbiology and Infectious Diseases \(ECCMID\)](#)
- Mar 22, 2018*
[Achaogen Announces New Employment Inducement Grants](#)
- Mar 21, 2018*
[Achaogen Announces Date of FDA Advisory Committee Meeting for Plazomicin](#)
- Mar 14, 2018*
[Achaogen to Present at Needham & Company's 17th Annual Healthcare Conference](#)

Financials [\[View all \]](#)

- [Fourth Quarter Financial Results](#)
- Feb 27, 2018*
[Annual Report \(10-K\)](#)
- Apr 18, 2018*
[Proxy Statement \(DEF 14A\)](#)
- Nov 8, 2017*
[Quarterly Report \(10-Q\)](#)
- Aug 8, 2017*
[Quarterly Report \(10-Q\)](#)
- May 8, 2017*
[Quarterly Report \(10-Q\)](#)